Clinical Trials Logo

Dwarfism, Pituitary clinical trials

View clinical trials related to Dwarfism, Pituitary.

Filter by:

NCT ID: NCT02946606 Completed - Clinical trials for Adult Growth Hormone Deficiency

A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9

Start date: January 2015
Phase: Phase 2
Study type: Interventional

This is a randomized, active-controlled, open-label, sequential dose group, Phase 1b/2 study designed to assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of weekly and every other week doses of GX-H9 in the treatment of AGHD.

NCT ID: NCT02781727 Completed - Clinical trials for Endocrine System Diseases

A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

Start date: December 13, 2016
Phase: Phase 3
Study type: Interventional

A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily. Approximately 150 prepubertal, hGH-treatment naïve children (males and females) with GHD will be included. Randomization will occur in a 2:1 ratio (TransCon hGH : Genotropin). This is a global trial that will be conducted in Armenia, Australia, Belarus, Bulgaria, Georgia, Greece, Italy, New Zealand, Poland, Romania, Russia, Turkey, Ukraine, and the United States.

NCT ID: NCT02693522 Completed - Clinical trials for Growth Hormone Deficiency

Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency

Start date: October 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of recombinant human growth hormone on adult growth hormone deficiency

NCT ID: NCT02580032 Completed - Clinical trials for Growth Hormone Deficiency in Children

Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)

Start date: October 5, 2015
Phase:
Study type: Observational

This study is conducted in Europe and the United States of America (USA). The aim of the study is to validate two measures for growth hormone deficiency in children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD).

NCT ID: NCT02558829 Completed - Clinical trials for Growth Hormone Deficiency With Pituitary Anomalies

Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency

Start date: December 3, 2015
Phase: Phase 3
Study type: Interventional

The Macimorelin Growth Hormone Stimulation Test (GHST) will be compared with the Insulin Tolerance Test (ITT) in an open-label, randomized, 2-way crossover Trial. The trial will include subjects suspected to have adult growth hormone deficiency (AGHD) and a group of healthy control subjects.

NCT ID: NCT02526420 Completed - Clinical trials for Adult Growth Hormone Deficiency

Versartis International Trial in Adults With Long-Acting Growth Hormone

VITAL
Start date: July 2015
Phase: Phase 2
Study type: Interventional

A Phase 2, open-label dose-finding safety study of individualized monthly VRS-317 dosing for five months in adults with GHD.

NCT ID: NCT02507245 Completed - Clinical trials for Growth Hormone Deficiency

Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD)

GHD
Start date: January 2014
Phase: N/A
Study type: Observational

The aim of this study is to assess the developmental patterns of lung function in children affected by growth hormone deficiency after one year of GH therapy.The assessment by specific questionnaires of quality of life and of parental stress index.Parameters will be evaluated at the time of the diagnosis and after 12 months of GH therapy.

NCT ID: NCT02382939 Completed - Clinical trials for Adult Growth Hormone Deficiency

A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency

REAL 2
Start date: February 12, 2015
Phase: Phase 3
Study type: Interventional

This trial is conducted in Europe and Asia. The aim of the trial is to compare the safety of once weekly dosing of somapacitan (administered with an investigational pen) with daily Norditropin® FlexPro® (somatropin delivered within a prefilled pen) for 26 weeks in previously human growth hormone (hGH) treated adults with growth hormone deficiency.

NCT ID: NCT02311894 Completed - Clinical trials for Growth Hormone Deficiency

A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency

Start date: March 31, 2015
Phase: Phase 4
Study type: Interventional

This is a Phase IV, multicenter, open-label, single-arm study of somatropin (rDNA origin) (Nutropin AQ v1.1) in pre-pubertal children with growth hormone deficiency (GHD) naïve to prior recombinant human growth hormone (rhGH) treatment. The study is designed to characterize the immunogenicity profile of somatropin (rDNA origin) injection when administered daily subcutaneously for 12 months. The clinical impact of immunogenicity will also be assessed.

NCT ID: NCT02229851 Completed - Clinical trials for Adult Growth Hormone Deficiency

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

REAL 1
Start date: October 31, 2014
Phase: Phase 3
Study type: Interventional

This study is conducted globally. The purpose is to demonstrate the efficacy of once weekly dosing of NNC0195-0092 (somapacitan) compared to placebo and once-daily dosing of somatropin (human growth hormone, hGH) after 35 weeks of treatment in adults with growth hormone deficiency.